Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149514 (
bronchitis
)
6,902
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serum tumor markers are useful for post-operative follow up, however, they are not necessarily useful for early stage diagnosis. Because the lesion is so small that it is unable to detect a tiny amount of their molecules in serum. If we could detect those antigens directly in cells from cytological specimens, it would provide a new diagnostic method for early stage cancers. The expression of carbohydrate antigens were examined with panel of specific anti-carbohydrate monoclonal antibodies (MAbs) on cytological specimens of sputum. In total, 146 sputa were collected in Sacomano's solution; 69 malignant cases (35 squamous cell carcinomas, 13 adenocarcinomas and 21 other primary lung cancers), 19 benign cases (pneumonia and
bronchitis
) and 58 borderline-malignancy cases which were defined by the standard of Japan Society of Lung Cancer. After removing mucus, the cells were stained with Vector's
ABC
method. Evaluation was performed by counting positively-stained cells among benign or atypical cells. As we examined previously in lung cancer tissue sections, there was statistical significance of frequency of positive stain between malignant and benign cases especially in MAbs AH6, THK2, SH1 and SNH3. Borderline malignancy gave intermediate value which means certain number of cells with cancerous biochemical character are mixed in the borderline specimens. In most cases, cell membrane was positively stained and sometimes, cytoplasm. Although the high sensitivity was observed in AH6 and SNH3, their specificity was lower than that of SH1, and visa versa. Those results indicate that the combination of anti-carbohydrate MAbs is useful for cytological diagnosis of lung cancer.
...
PMID:[Detection of carbohydrate antigens of malignant cells in sputum with panel of monoclonal antibodies]. 836 Oct 31
To illustrate a previously unreported method of tracheal stent removal that appears to cause less mucosal injury we present a case of a 9-year-old Down syndrome patient with a history of tracheoesophageal fistula, brought to our attention after recurrent bouts of exacerbating cough and tracheo-
bronchitis
. Endoscopic examination under general anesthesia noted the presence of severe tracheomalacia with inspiratory collapse, and a 10-mm balloon expandable metallic stent (BEMS) was deployed and symptomatic improvement was noted. The initial stent was then removed to consider a definitive procedure using the typical grasping fashion with an alligator forceps and expected mucosal excoriation was noted. Due to symptom recurrence, the patient underwent placement of a second BEMS stent. Initial improvement was noted followed by recurrent episodes of respiratory distress due to granulation tissue formation and stent compression and a decision to remove the stent was made. A new method of stent removal deemed
ABC
(airway balloon collapse) method was utilized where an expandable airway balloon is placed outside the stent between the stent and tracheal wall and then inflated to collapse the stent, facilitating easy removal.
...
PMID:Endotracheal metallic stent removal: A novel ABC (airway balloon collapse) technique. 3322 32